

Gibson Dunn Advises Merck on \$10 Billion Verona Pharma Acquisition

Firm News | July 9, 2025

Gibson Dunn is advising Merck & Co., Inc., one of the world's largest pharmaceutical companies, on its \$10 billion acquisition of Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases. The Gibson Dunn antitrust team includes partners Steve Weissman and Michael Perry and associate Tristan Locke.

Related People

[Stephen Weissman](#)

[Michael J. Perry](#)

[Tristan Locke](#)

Related Capabilities

[Antitrust and Competition](#)